On Target touts study on intraoperative imaging agent

By AuntMinnie.com staff writers

September 16, 2022 -- Molecular imaging agent developer On Target Laboratories is highlighting the results of a study showing the effectiveness of its Cytalux (pafolacianine) agent in intraoperative imaging of folate receptor-positive ovarian cancer.

In a study published September 7 in the Journal of Clinical Oncology, researchers reported data from 150 patients who received a single infusion of Cytalux during ovarian cancer surgery.

They found that in 33% of the 109 patients with folate receptor-positive ovarian cancer, near-infrared imaging with Cytalux identified additional lesions that would have been left behind (p < 0.001).

Furthermore, the researchers found that the rate of additional lesion detection was higher, at 39.7%, among patients who underwent interval debulking surgery, Cytalux said.

Copyright © 2022 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking